Brain cancer vaccine trial aims to boost survival
NCT ID NCT02455557
Summary
This study is testing whether adding an experimental vaccine called SurVaxM to standard chemotherapy (temozolomide) can help control a serious brain cancer called glioblastoma. The vaccine is designed to teach the body's immune system to recognize and attack cancer cells. The trial will enroll 66 adults with newly diagnosed glioblastoma to see if the combination is safe and can help delay the cancer's return and extend life.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beth Israel Deaconess Medical Center
Boston, Massachusetts, 02215, United States
-
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center
Cleveland, Ohio, 44195, United States
-
Dana-Farber Harvard Cancer Center
Boston, Massachusetts, 02115, United States
-
Massachusetts General Hospital Cancer Center
Boston, Massachusetts, 02114, United States
-
Roswell Park Cancer Institute
Buffalo, New York, 14263, United States
Conditions
Explore the condition pages connected to this study.